Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Laurent Fischer | M | 60 | 4 years | |
| Peter Soparkar | M | 53 | 5 years | |
| Scott Whitcup | M | 64 | 4 years | |
| Jim Scopa | M | 65 | 5 years | |
| Mark Lupher | M | 53 | 5 years | |
| Reed Tuckson | M | 73 | 3 years | |
| Dawn Svoronos | F | 70 | 4 years | |
| Heikki Jouttijärvi | M | - | 4 years | |
| Derek Lionel Glendon Hill | M | 58 |
University College London
| 29 years |
| Robert Karsunky | M | - |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 11 years |
| Mark Lowdell | M | 61 |
University College London
| 30 years |
| Dena House | F | - | 5 years | |
| Bill Tan | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Cleveland | M | 67 | 4 years | |
| Ian Clark | M | 62 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 13 years |
| Jennifer Cheng | M | 51 | 4 years | |
| Christopher J. DeRespino | M | 43 | - | |
| Myesha Lacy | F | - | - | |
| Ee-Eul Kim | M | 54 |
University College London
| 7 years |
| Dong-Suk Sin | M | 53 |
University College London
| 4 years |
| Jerry Cacia | M | 57 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 28 years |
| William Anderson | M | 57 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
| Angela Thedinga | F | 42 | 2 years | |
| Rekha Hemrajani | F | 54 | 2 years | |
| Ee Leng Aw | F | 50 |
University College London
| 4 years |
| Michael Bell | M | 55 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 4 years |
| Mitchell Finer | M | 65 | 13 years | |
| Iain David Wright | M | 52 |
University College London
| 5 years |
| Martina A. Sersch | M | 54 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 5 years |
| Daniel S. Chen | M | 55 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 12 years |
| Vera Tan | F | 46 |
University College London
| 4 years |
| Maria Forero | F | - |
University College London
| 4 years |
| Richard Kunzer | M | - |
University College London
| 3 years |
| Pak Lun Yu | M | 52 |
University College London
| 4 years |
| Robin Ali | M | - |
University College London
| 3 years |
| Anna Wyse | F | 46 |
University College London
| 4 years |
| Yin Chee Mak | F | 55 |
University College London
| 4 years |
| Chung Ho Tsui | M | 45 |
University College London
| 4 years |
| Kenneth Harrison | M | 44 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 2 years |
| Edward T. L. Cheung | M | 54 |
University College London
| 4 years |
| Stacey Ma | M | 54 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 4 years |
| Andrea Pirzkall | M | 54 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 10 years |
| David Crawford | M | - |
University College London
| 3 years |
| Shang Lee | F | 51 |
University College London
| 4 years |
| Bjørn Tore Urdal | M | - |
University College London
| 1 years |
| Yee Ling Tsang | F | 47 |
University College London
| 4 years |
| Tapan Maniar | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 4 years |
| Stefano de Vivo | M | 46 |
University College London
| 4 years |
| Michel Lee | M | - |
University College London
| 2 years |
| Kong Yin Mak | F | 50 |
University College London
| 4 years |
| Ahilan Yogadeva | M | - |
University College London
| 3 years |
| Debojit Mukherjee | M | - |
University College London
| 3 years |
| Micki Klearman | M | 69 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 years |
| Donna French | M | 59 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 years |
| Lauren Merendino | F | 49 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 years |
| Lisa Bowers | F | 51 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 2 years |
| Edith Perez | M | 67 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 years |
| Elliot Richmond | M | 45 |
University College London
| 3 years |
| Asha Collins | M | 48 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 years |
| Matthew Quinlan | M | 51 |
University College London
| 4 years |
| Mee Yau Pok | F | 45 |
University College London
| 3 years |
| James Reid Desmond Arthur | M | 47 |
University College London
| 3 years |
| Uzoma Chukwumaeze Dozie | M | 55 |
University College London
| 1 years |
| Tiia Silja Kristiina Tuovinen | F | 59 |
University College London
| 1 years |
| Rebecca Hobby | F | - |
University College London
| 4 years |
| Andrew J. Mullins | M | 42 |
University College London
| 4 years |
| Frédéric Zoller | M | - |
University College London
| 5 years |
| Xavier Thiran | M | - |
University College London
| 4 years |
| Janusz Ryszard Diemko | M | 55 |
University College London
| 4 years |
| Dheeraj Gopichand Hinduja | M | 52 |
University College London
| 4 years |
| Daniel Perrin | M | - |
University College London
| 4 years |
| Boon Seng Heng | M | 48 |
University College London
| 4 years |
| Sam Julian Barron-Fox | M | - |
University College London
| 4 years |
| Peter Lawson | M | - |
University College London
| 4 years |
| Joseph Brooks | M | 54 |
University College London
| 3 years |
| Hideki Garren | M | 60 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 2 years |
| David C. Egan | M | - |
University College London
| 3 years |
| Nick Coleman | M | - |
University College London
| 3 years |
| Ian Philliskirk | M | - |
University College London
| 3 years |
| Chek Siong Tan | M | 43 |
University College London
| 4 years |
| Reyer Zwiggelaar | M | - |
University College London
| 3 years |
| Samer Abdin | M | - |
University College London
| 4 years |
| Dany Farha | M | 52 |
University College London
| 3 years |
| Chun Fai Ng | M | 52 |
University College London
| 4 years |
| Victor Ofstein | M | - |
University College London
| 4 years |
| Damian T. Burke | M | 51 |
University College London
| 4 years |
| Yong Chien Tan | M | 34 |
University College London
| 14 years |
| Angus Urquhart | M | - |
University College London
| 4 years |
| Rob Shimell | M | - |
University College London
| 4 years |
| Steve Gibson | M | - |
University College London
| 3 years |
| Ush Patel | M | - |
University College London
| 1 years |
| Emmanuel Baah | M | - |
University College London
| 4 years |
| Maximilian Bittner | M | 45 |
University College London
| 4 years |
| Chung Ching Chan | M | 48 |
University College London
| 3 years |
| Peter Francis | M | 55 |
University College London
| 3 years |
| Brian Armstrong | M | 63 |
University College London
| 3 years |
| James Daniel Macey | M | 46 |
University College London
| 2 years |
| Anand Kumaresh Tharmaratnam | M | 54 |
University College London
| 3 years |
| Alexandros Sinka | M | 46 |
University College London
| 3 years |
| Aristeidis Kypriotis | M | - |
University College London
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 65 | 65.00% |
| United States | 32 | 32.00% |
| Switzerland | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Aaron Osborne
- Personal Network
